Serum markers to detect metastatic uveal melanoma

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1897-1900

  Barak, Vivian ^a   Frenkel, Shachar ^a   Kalickman, Inna ^a   Maniotis, Andrew J ^b   Folberg, Robert ^b   Pe'er, Jacob ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Markers; Metastasis; MIA; Osteopontin; S 100; Uveal melanoma

Indexed keywords

MELANOMA INHIBITORY ACTIVITY PROTEIN; OSTEOPONTIN; PROTEIN S100B; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; CANCER DIAGNOSIS; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UVEA MELANOMA;

AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; OSTEOPONTIN; ROC CURVE; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 34250766584     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Damato B: Developments in the management of uveal melanoma. Clin Exp Ophthalmol 32: 639-647, 2004.
2. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A and Rennie IG: A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathol 45: 1-12, 2004.
3. Kaiserman I, Amer R and Pe'er J: Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137(2): 236-243, 2004.
4. Toivonen P, Makitie T, Kujala E and Kivela T: Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci 45: 1-6, 2004.
5. Hannsson L, Hauschild A, Bonfrer JMG, Duffy J and Einarsson R: Tumor markers in malignant melanoma - EGTM (European Group on Tumor Markers) Guidelines. Tumor Biol 27: 35-S1, 2006.
6. Bonfrer, JMB et al: The luminescence immunoassay S-100: a sensitive test to measure circulating S-100β: its prognostic value in malignant melanoma. Br J Cancer 77: 2210-2214, 1998.
7. Bosserhoff AK et al: Melanoma-inhibiting activity: MIA - a novel serum for progression of malignant melanoma. Cancer Res 57: 3149-3153, 1997.
8. Hauschild A: Prospective evaluation on the utility of S-100β and technical staging procedures in the follow up of melanoma patients. Tumor Biol 24: S1, 60, 2003.
9. Hauschild A et al: S-100β-protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56: 338-344, 1999.
10. Missotten GS, Tang NE, Korse CM et al: Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthal 121: 1117-1119, 2003.
11. Rittling SR and Chambers AF: Role of osteopontin in tumor progression. British J Cancer 90: 1877-1881, 2004.
12. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS and Chambers AF: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508, 1998.
13. Kadkol S, Lyn A, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis A, Folberg R and Pe'er J: Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. IOVS 47(3): 802-806, 2006.
14. Metz CE: Quantitative ROC analysis. Basic principles of ROC analysis. Sem Nuc Med 8: 283-298, 1978.
15. Peer J, Nir I, Lotem M, Folberg R and Frenkel S: Post hepatectomy survival of metastatic uveal melanoma patients. IOVS 47: ARVO E-Abstract 1497, 2006.
16. Donoso LA, Shields JA, Augsburger JA, Orth DH, Johnson P: Metastatic uveal melanoma: diffuse hepatic metastasis in a patient with concurrent normal serum enzyme levels and liver scan. Arch Ophthalmol 103: 758-760, 1985.
17. Kaiserman I, Amer R and Pe'er J: Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137: 236-243, 2004.